Navigation Links
New Jefferson trial to test radiation-emitting beads against advanced liver cancer
Date:2/12/2008

(PHILADELPHIA) Liver cancer specialists at Jeffersons Kimmel Cancer Center in Philadelphia are beginning an 18-month study of a new treatment for liver cancer. The therapy entails injecting tiny beads that emit small amounts of radiation into the livers main artery while also blocking the blood supply feeding the cancers growth.

The technique, called radioembolization, has been approved by the federal Food and Drug Administration for use in inoperable liver cancer. This is the first time that the particular technology, called SIR-Spheres microspheres, which is FDA-approved for treating colon cancer that has spread to the liver, is being studied in patients with hepatocellular carcinoma, or primary liver cancer (cancer that originates in the liver). The trial, which is led by Brian Carr, M.D., FRCP, Ph.D., professor of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, includes patients from the University of Texas M.D. Anderson Cancer Center in Houston and the University of Pittsburgh.

According to Dr. Carr, who is chief of the liver tumor program at the Kimmel Cancer Center and Thomas Jefferson University Hospital, the technique uses approximately 30-times more beads than other types or radioembolization. The teams plan to enroll 10 patients initially, and perhaps as many as 40 altogether. No one knows if radioembolization will be better than just radiation, even though there are theoretical grounds for it, he notes.

In the form of radioembolization being tested, millions of tiny beads or microspheres containing the radioactive isotope Yttrium-90 are injected through a catheter directly into the livers hepatic artery, which also supplies blood to tumors. The microspheres, in addition to blocking blood flow to the tumor, emit targeted radiation directly to the cancer, sparing healthy tissue.

Dr. Carr and his colleagues are encouraged by results from a recent clinical trial showing the effectiv
'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
2. Jefferson immunology researchers halt lethal rabies infection in brain
3. Jefferson radiation oncologists use real-time system to plant seeds against cancer
4. Jefferson researchers find personalized interventions key to improving colon cancer screening rates
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
7. Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
10. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
11. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 1Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 2Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 3Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 1Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 2Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 3Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 4Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 1Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 2Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 3Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 4Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 5Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 6Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 7Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 8Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 9